|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002844,
umls-concept:C0205179,
umls-concept:C0282461,
umls-concept:C0376358,
umls-concept:C0439608,
umls-concept:C0442711,
umls-concept:C0871712,
umls-concept:C1514695,
umls-concept:C1517927,
umls-concept:C1522577,
umls-concept:C2926735
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2008-5-19
|
|
pubmed:abstractText |
To determine whether adding 2 years of androgen-deprivation therapy (ADT) improved outcome for patients electively treated with ADT before and during radiation therapy (RT).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BaeKyounghwaK,
pubmed-author:BreretonHarmar DHD,
pubmed-author:GrignonDavid JDJ,
pubmed-author:HanksGerald EGE,
pubmed-author:HorwitzEric MEM,
pubmed-author:LawtonColleen ACA,
pubmed-author:PorterArthurA,
pubmed-author:RosenthalSeth ASA,
pubmed-author:SandlerHoward MHM,
pubmed-author:ShipleyWilliam UWU,
pubmed-author:VenkatesanVaragurV
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2497-504
|
|
pubmed:meshHeading |
pubmed-meshheading:18413638-Adenocarcinoma,
pubmed-meshheading:18413638-Adult,
pubmed-meshheading:18413638-Aged,
pubmed-meshheading:18413638-Aged, 80 and over,
pubmed-meshheading:18413638-Androgen Antagonists,
pubmed-meshheading:18413638-Combined Modality Therapy,
pubmed-meshheading:18413638-Follow-Up Studies,
pubmed-meshheading:18413638-Humans,
pubmed-meshheading:18413638-Male,
pubmed-meshheading:18413638-Middle Aged,
pubmed-meshheading:18413638-Neoplasm Staging,
pubmed-meshheading:18413638-Prognosis,
pubmed-meshheading:18413638-Prostatic Neoplasms,
pubmed-meshheading:18413638-Survival Rate,
pubmed-meshheading:18413638-Time Factors,
pubmed-meshheading:18413638-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
|
|
pubmed:affiliation |
Fox Chase Cancer Center, Department of Radiation Oncology, 333 Cottman Ave, Philadelphia, PA 19111-2497, USA. eric.horwitz@fccc.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase III,
Research Support, N.I.H., Extramural
|
